CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in San Diego, California. The company went public in July 2018 and focuses on developing innovative oral therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics has built a robust pipeline centered around nonpeptide small molecule drugs that target hormone receptors, with its lead candidate <b>paltusotine</b> nearing FDA approval for acromegaly treatment. The company has evolved from a research-focused organization to one preparing for commercial launch, with substantial cash reserves of approximately $1.4 billion to fund operations through 2029.